❌

Reading view

There are new articles available, click to refresh the page.

Millions of Americans are not taking their GLP-1 drugs as prescribed

GLP-1 medications are everywhere these days. The peptide-based drugs are both highly effective and wildly popular for diabetes, weight loss and a growing range of connected chronic health conditions, including cardiovascular disease and obstructive sleep apnea. But, amid the boom, the latest data suggests millions of Americans have turned to unapproved versions and are using the potent drugs in ways doctors never intended, raising questions about what that real-world use means for safety and efficacy.

In a study published this week, researchers at the Centers for Disease Control and Prevention broke down survey data of GLP-1 use collected between July and August of 2025. Based on responses from over 8,000 US adults, the researchers estimate that about one in 10 US adults (9.8 percent) used a glucagon-like peptide-1 receptor agonist, aka GLP-1 medication, in 2025. That's around 27 million adults. The study was published in the CDC's Morbidity and Mortality Weekly Report.

Among GLP-1 users, nearly half (44 percent) reported using their GLP-1 in a way that was different from how it was prescribed. Users skipped doses, delayed getting refills, and used smaller doses than prescribed, among other changes. More than half of the people modifying how they used the drug said the changes were because of cost or availability reasons. Cost and access barriers were most pronounced among younger GLP-1 users. Fifty-eight percent of adults 14­–39 years old who modified their use cited cost as a barrier, compared with just 20 percent of adults 65 or older who said the same.

Read full article

Comments

Β© Getty | Munro

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

The Food and Drug Administration is warning that popular obesity drugsβ€”including Ozempic, Wegovy, Zepbound, and Mounjaroβ€”may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss.

In a drug safety communication Monday, the FDA said it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on their drug labels. The specific eye condition it warns of is called non-arteritic anterior ischemic optic neuropathy or NAION. The condition is caused by restricted blood flow to the optic nerve, which leads to swelling and cell death and ultimately damages the nerve, causing abrupt vision loss that can often be permanent.

It's unknown how GLP-1 drugs may cause NAION. The condition is rare overall, occurring in somewhere between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmology. These small numbers have made it more difficult to determine with certainty if there is a connection. Further complicating the potential link is the fact that the risk factors for developing NAION are common among patients taking GLP-1 drugs. The risk factors include diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome, and obstructive sleep apnea.

Read full article

Comments

Β© Getty | George Pachantouris

❌